Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pathological complete response, (pCR) correlates with a favourable overall prognosis in locally advanced rectal cancer patients underwent preoperative chemoradiation, so obtaining a pCR might be beneficial. The aim of the study is to investigate safety and efficacy of preoperative IMRT combined with bevacizumab and capecitabine. primary endpoint is pathological complete remission rate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer

NCT02195141

Rectal Cancer

UNKNOWN PHASE2

A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma

NCT00973778

Chemoradiotherapy

UNKNOWN PHASE2

Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00084591

Colorectal Cancer

COMPLETED PHASE1

Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

NCT03381352

Anal Cancer

UNKNOWN PHASE2

A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer

NCT03245203

Rectal Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Locally Advanced Malignant Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

preoperative chemoradiation

* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),
* bevacizumab: at dose 5 mg/kg on days -1, 15,31.
* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.

Group Type EXPERIMENTAL

chemoradiation

Intervention Type RADIATION

* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),
* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.
* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

chemoradiation

* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),
* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.
* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Preoperative Radiotherapy With Capecitabine and Bevacizumab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients with histologically proven adenocarcinoma of the rectum ,T3/4 or any node positive disease (clinical stage according the TNM classification system)
* No evidence of metastatic disease.
* Age 18 - 65 years
* Kps 80-100
* No prior radiotherapy, chemotherapy or any targeting therapy for rectal cancer
* Normal hematological, hepatic and renal function, Ability to swallow tablets
* Signed informed consent
* Patients must be willing and able to comply with the protocol for duration of the study

Exclusion Criteria

* Malignancy of the rectum other than adenocarcinoma

* Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin
* Significant heart disease (uncontrolled hypertension despite of medication (\> 150/100 mmHg), NYHA class III or IV heart disease,unstable angina or myocardial infarction within the past 1 year prior the study entry, history of significant ventricular arrhythmia requiring treatment)
* Evidence of active peptic ulcer or upper GI bleeding
* Evidence of bleeding diathesis or coagulopathy
* Patients receiving a concomitant treatment with drugs interacting with capecitabine such as flucitosine, phenytoin, or warfarin
* Known hypersensitivity to biological drugs
* Treatment with any investigational drug within 30 days before beginning treatment with the study drug
* Pregnant or lactating patient

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No